The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of SLCO transport genes with intraprostatic abiraterone (ABI) levels and pathologic outcomes in men with high-risk localized prostate cancer (PCa).
 
Elahe A. Mostaghel
No Relationships to Disclose
 
Eunpi Cho
No Relationships to Disclose
 
Jonathan Lawrence Wright
No Relationships to Disclose
 
Massimo Loda
No Relationships to Disclose
 
Brett Marck
No Relationships to Disclose
 
Alvin M. Matsumoto
Consulting or Advisory Role - Abbvie; Claris; Lilly
Research Funding - Abbvie; DPKO; GlaxoSmithKline
 
Daniel Tamae
No Relationships to Disclose
 
Trevor M. Penning
Stock and Other Ownership Interests - Penzymes
Consulting or Advisory Role - Sage Therapeutics; Tokai Pharmaceuticals
 
Steven P. Balk
Speakers' Bureau - Astellas Pharma; Dendreon; Johnson & Johnson
Research Funding - Tokai Pharmaceuticals
 
Philip W. Kantoff
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Metamark Genetics
Consulting or Advisory Role - Amgen; Aragon Pharmaceuticals; Archimedes; Astellas Pharma; Auven Therapeutics; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Celgene; Dendreon; Endocyte; Exelixis; Genomic Health; GTx; Janssen; Medivation; Merck; Metamark Genetics; Millennium; MorphoSys; MTG Therapeutics; OncoCellMDX; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Sotio; Teva; Tokai Pharmaceuticals
Research Funding - Amgen (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Bayer (Inst); Dendreon (Inst); Exelixis (Inst); Janssen Oncology (Inst); Medivation (Inst); Oncogenex (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bavarian Nordic; BIND Biosciences; Janssen; Millennium; Progenics; Sanofi
 
Peter Nelson
Honoraria - Janssen Research & Development
Consulting or Advisory Role - Janssen Research & Development
 
Mary-Ellen Taplin
Honoraria - Bayer; Dendreon; Janssen-Ortho; Medivation; Tokai Pharmaceuticals
Consulting or Advisory Role - Bayer; Best Doctors, Inc; Dendreon; Gerson Lehrman Group; Guidepoint Global; Janssen-Ortho; Medivation; Sanofi; Tokai Pharmaceuticals; UpToDate
Research Funding - Bayer; Genentech; Janssen-Ortho; Medivation
Travel, Accommodations, Expenses - Dendreon; Janssen Oncology; Medivation; Tokai Pharmaceuticals
 
Robert B. Montgomery
Research Funding - Essa; Janssen; Medivation; Tokai Pharmaceuticals